Metabolic Effects of Selected Traditional and Alternative Sweeteners: A Narrative Review

If you formulate reduced-sugar products, you need to know which sweeteners do more than taste sweet. The metabolic response to a sweetener changes how your product acts in the body. A recent narrative review in Nutrients (DOI: 10.3390/nu16050622) examines selected traditional and alternative sweeteners. The authors set the stage with sugar's known harms, then zero in on substitutes with favorable metabolic effects.

Background: Sugar's known toll

Excessive sugar consumption drives overweight and type II diabetes mellitus. That's well established. The review asks a sharper question: can any sweetener flip the script? It names xylitol, erythritol, and D-allulose as the most promising alternatives. All three show favorable metabolic outcomes compared with sugar.

What the review covered

The authors did not run a new clinical trial. They conducted a narrative review of existing studies. That means they selected relevant research and summarized the patterns across it. The focus is metabolic effects, not just sweetness or shelf life. For formulators, that's exactly the right lens. Taste matters, but the biological response is where product differentiation starts.

Key findings at a glance

The acute human data on erythritol and D-allulose stand out. The table below captures the published responses.

Sweetener	Dose studied	Gut hormone response
Erythritol	10 to 75 g, given intragastrically or orally	Increased GLP-1, CCK, and PYY; no change in GIP
D-Allulose	25 g in healthy, normal-weight adults	Increased GLP-1, PYY, and CCK

Let's unpack the abbreviations. GLP-1 is glucagon-like peptide-1. PYY is peptide YY. CCK is cholecystokinin. These hormones influence appetite and glycemic control. GIP is glucose-dependent insulinotropic polypeptide. Erythritol's lack of a GIP response is notable. A sweetener that raises satiety signals without nudging GIP may fit weight-management products more cleanly.

What this means for manufacturers

You can now sort sweeteners by their biological effects, not just their glycemic index. Erythritol and D-allulose bring a metabolic story that sugar cannot. That opens doors for satiety-focused snacks, diabetic-friendly beverages, and meal replacements.

But dose matters. The erythritol data used 10 to 75 g per acute exposure. The allulose data used 25 g. A typical serving of a beverage or bar may deliver less than that. You need to decide whether your target dose reaches the threshold that triggers a measurable hormone response. The review gives you a benchmark, not your answer.

Formulators should pair this evidence with practical testing. Sweetness intensity, solubility, and aftertaste still rule the bench. Add metabolic response to that list. Then run consumer panels to see how the product performs in real life. The science here is strong enough to guide your shortlist, but it doesn't replace application work.

FAQ

Why should I care about GLP-1 if I'm not making a diabetic product?

GLP-1 affects appetite and insulin secretion. That makes it relevant for any product with a satiety or weight-management angle. Even consumers who aren't diabetic respond to those signals.

Does erythritol's lack of GIP response mean it's better than D-allulose?

The review doesn't rank them. Both show favorable profiles. Erythritol raised three satiety-related hormones without touching GIP. D-allulose raised the same three hormones in healthy, normal-weight adults. Your choice depends on sweetness profile, digestive tolerance, and application.

Can I use these findings to support a satiety claim on product labels?

Not directly. This review summarizes scientific evidence. Regulatory approval for claims follows a separate process. Bring the paper to your regulatory team and let them assess what you can say in your market.

The next time you benchmark sweeteners, put metabolic response on the same checklist as sweetness, solubility, and cost. This review gives you a useful starting point. Erythritol and D-allulose deserve a closer look. The rest is up to your formulation team.